[go: up one dir, main page]

WO2001072278A3 - Method for administering insulin to the buccal region - Google Patents

Method for administering insulin to the buccal region Download PDF

Info

Publication number
WO2001072278A3
WO2001072278A3 PCT/IB2001/000564 IB0100564W WO0172278A3 WO 2001072278 A3 WO2001072278 A3 WO 2001072278A3 IB 0100564 W IB0100564 W IB 0100564W WO 0172278 A3 WO0172278 A3 WO 0172278A3
Authority
WO
WIPO (PCT)
Prior art keywords
acid
absorption enhancing
enhancing compounds
formulation
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2001/000564
Other languages
French (fr)
Other versions
WO2001072278A2 (en
Inventor
Pankaj Modi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Generex Pharmaceuticals Inc
Original Assignee
Generex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/538,829 external-priority patent/US7070799B1/en
Application filed by Generex Pharmaceuticals Inc filed Critical Generex Pharmaceuticals Inc
Priority to AU44452/01A priority Critical patent/AU4445201A/en
Publication of WO2001072278A2 publication Critical patent/WO2001072278A2/en
Publication of WO2001072278A3 publication Critical patent/WO2001072278A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Otolaryngology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

A mixed micellar pharmaceutical formulation includes a micellar proteinic pharmaceutical agent, an alkali metal C8 to C22 alkyl sulphate, alkali metal salicylate, a pharmaceutically acceptable edetate and at least one absorption enhancing compounds. The absorption enhancing compounds are selected from the group consisting of lecithin, hyaluronic acid, pharmaceutically acceptable salts of hyaluronic acid, octylphenoxypolyethoxyethanol, glycolic acid, lactic acid, chamomile extract, cucumber extract, oleic acid, linolenic acid, borage oil, evening of primrose oil, trihydroxy oxo cholanylglycine, glycerin, polyglycerin, lysine, polylysine, triolein and mixtures thereof. The amount of each absorption enhancing compound is present in a concentration of from 1 to 10 wt./wt.% of the total formulation, and the total concentration of absorption enhancing compounds are less than 50 wt./wt.% of the formulation.
PCT/IB2001/000564 2000-03-30 2001-02-21 Method for administering insulin to the buccal region Ceased WO2001072278A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU44452/01A AU4445201A (en) 2000-03-30 2001-02-21 Method for administering insulin to the buccal region

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/538,829 US7070799B1 (en) 1998-02-10 2000-03-30 Method for administering insulin to the buccal region
US09/538,829 2000-03-30

Publications (2)

Publication Number Publication Date
WO2001072278A2 WO2001072278A2 (en) 2001-10-04
WO2001072278A3 true WO2001072278A3 (en) 2002-04-11

Family

ID=24148588

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2001/000564 Ceased WO2001072278A2 (en) 2000-03-30 2001-02-21 Method for administering insulin to the buccal region

Country Status (2)

Country Link
AU (1) AU4445201A (en)
WO (1) WO2001072278A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107583047A (en) * 2017-09-15 2018-01-16 广东海大畜牧兽医研究院有限公司 A kind of fish oral vaccine adjuvant and its formulation method

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1369113B1 (en) * 2002-06-06 2006-11-22 CHIESI FARMACEUTICI S.p.A. Solubilisation of drugs in HFA propellant by means of emulsions
FR2854072B1 (en) * 2003-04-23 2006-08-04 Centre Nat Rech Scient VECTOR FOR ORAL ADMINISTRATION
GB2430881B (en) 2005-10-06 2010-10-13 Ntnu Technology Transfer As Oligoelectrolyte polyols for the treatment of mucosal hyperviscosity
GB0707096D0 (en) 2007-04-12 2007-05-23 Ntnu Technology Transfer As Method
GB0904941D0 (en) 2009-03-23 2009-05-06 Ntnu Technology Transfer As Composition
GB0904942D0 (en) * 2009-03-23 2009-05-06 Ntnu Technology Transfer As Composition
US11166912B2 (en) * 2016-03-03 2021-11-09 Ctt Pharma Inc. Orally administrable composition
US11298336B2 (en) 2019-05-30 2022-04-12 Soluble Technologies, Inc. Water soluble formulation
US11786475B2 (en) 2020-07-22 2023-10-17 Soluble Technologies Inc. Film-based dosage form

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994026302A1 (en) * 1993-05-12 1994-11-24 Genentech, Inc. Stable liquid compositions of gamma interferon
WO1996019197A1 (en) * 1994-12-22 1996-06-27 Astra Aktiebolag Aerosol formulations of peptides and proteins
WO1996036352A1 (en) * 1995-05-16 1996-11-21 Pankaj Modi Liquid formulations for proteinic pharmaceuticals comprising at least 2 absorption enhancers
WO1999040932A1 (en) * 1998-02-10 1999-08-19 Generex Pharmaceuticals, Inc. Mixed micellar pharmaceutical delivery system and method of preparation
WO2000037051A1 (en) * 1998-12-21 2000-06-29 Generex Pharmaceuticals Inc. Aerosol formulations for buccal and pulmonary application
WO2001015666A1 (en) * 1999-08-31 2001-03-08 Generex Pharmaceuticals Inc. Mixed micellar pharmaceutical delivery system and method of preparation

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994026302A1 (en) * 1993-05-12 1994-11-24 Genentech, Inc. Stable liquid compositions of gamma interferon
WO1996019197A1 (en) * 1994-12-22 1996-06-27 Astra Aktiebolag Aerosol formulations of peptides and proteins
WO1996036352A1 (en) * 1995-05-16 1996-11-21 Pankaj Modi Liquid formulations for proteinic pharmaceuticals comprising at least 2 absorption enhancers
WO1999040932A1 (en) * 1998-02-10 1999-08-19 Generex Pharmaceuticals, Inc. Mixed micellar pharmaceutical delivery system and method of preparation
WO2000037051A1 (en) * 1998-12-21 2000-06-29 Generex Pharmaceuticals Inc. Aerosol formulations for buccal and pulmonary application
WO2001015666A1 (en) * 1999-08-31 2001-03-08 Generex Pharmaceuticals Inc. Mixed micellar pharmaceutical delivery system and method of preparation

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
YAMAMOTO A ET AL: "Pulmonary absorption enhancement of peptides by absorption enhancers and protease inhibitors", JOURNAL OF CONTROLLED RELEASE, vol. 41, no. 1, 1 August 1996 (1996-08-01), pages 57-67, XP004037571 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107583047A (en) * 2017-09-15 2018-01-16 广东海大畜牧兽医研究院有限公司 A kind of fish oral vaccine adjuvant and its formulation method

Also Published As

Publication number Publication date
WO2001072278A2 (en) 2001-10-04
AU4445201A (en) 2001-10-08

Similar Documents

Publication Publication Date Title
CA2382535A1 (en) Mixed micellar pharmaceutical delivery system and method of preparation
BR9804295A (en) Mixed micellar release system and method of preparation.
NZ512188A (en) Micelle aerosol formulations for buccal and pulmonary application
SI1313510T1 (en) Injectable pharmaceutical composition for systemic delivery of pharmacologically active compounds comprising medium chain triglycerides
WO2001066085A3 (en) Micellar pharmaceutical compositions for buccal and pulmonary application
AU2001237397B2 (en) Dual composition cosmetic product with a concentration sensitive and an incompatible active respectively placed within first and second compositions
WO2001072278A3 (en) Method for administering insulin to the buccal region
MXPA02011436A (en) Micellar pharmaceutical compositions for buccal and pulmonary application.
WO2004016244A3 (en) Pharmaceutical compositions for buccal delivery of pain relief medications
EP0406162A3 (en) Process for the preparation of a nanoemulsion of oilparticles in an aqueous phase
JP2000154136A (en) Skin-bleaching composition containing the extract of bearberry (arctostaphylos uva-ursi) and reducing agent
ATE202698T1 (en) TOPICALLY APPLICABLE PHARMACEUTICAL COMPOSITION, METHOD FOR THE PRODUCTION THEREOF AND USE OF THE COMPOSITION
KR860007370A (en) Emulsion Mousse Composition for Skin Cleansing
TW359616B (en) A parenterally administered pharmaceutical composition for lipophilic, poorly soluble active compounds, in the form of liposomes with phospholipid membranes
SG143019A1 (en) Pharmaceutical compositions for oral and topical administration
GR3035613T3 (en) Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids
US6217913B1 (en) Cosmetic compositions with gorgonian extract
EP1002525A3 (en) N-acylate derivatives of pyrrolidone carboxylic acid as surfactant
EP1219288A3 (en) Treatment for skin
CA2229286A1 (en) Mixed micellar delivery system and method of preparation
JP6984394B2 (en) Underwater oil type emulsified cosmetic
ATE324103T1 (en) CONTROLLED RELEASE MEDICINAL PREPARATION CONTAINING TRAMADOL HYDROCHLORIDE
KR940013503A (en) Pharmaceutical compositions for the prevention or treatment of atherosclerosis
CA2364610A1 (en) Pharmaceutical solubilized in aerosol propellant
JPH0948962A (en) Agent that inhibits solidification of liquid

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP